| 产品描述: | LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors |
| 靶点: |
Survivin |
| 体外研究: |
LQZ-7I (10 µM; 0-6 hours) treatment reduces the expression of survivin. However, LQZ-7I does not reduce the expression of XIAP, CIAP1, and CIAP2. LQZ-7I may be selective to its intended target survivin. Western Blot Analysis Cell Line: PC-3 or C4-2 cells Concentration: 10 µM Incubation Time: 0-6 hours Result: Reduced the expression of survivin. |
| 体内研究: |
LQZ-7I (100 mg/kg; oral gavage every other day for a total of ten treatments) significantly suppresses tumor growth without any notable adverse effect on the mice. Animal Model: 6-week old male NSG mice Dosage: 100 mg/kg; 200 µL vehicle (90% corn oil/10% DMSO) Administration: Oral gavage every other day for a total of ten treatments Result: Significantly suppressed tumor growth without any notable adverse effect on the mice as indicated by lacking changes in body weight and in wet weight of major organs at the end of the study. |
| 参考文献: |
1. Robert Peery,et al. Synthesis and Identification of a Novel Lead Targeting Survivin Dimerization for Proteasome-Dependent Degradation. J Med Chem. 2020 Jun 9. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.871 ml |
14.353 ml |
28.707 ml |
| 5 mM |
0.574 ml |
2.871 ml |
5.741 ml |
| 10 mM |
0.287 ml |
1.435 ml |
2.871 ml |
| 50 mM |
0.057 ml |
0.287 ml |
0.574 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |